Expert Interviews

Dr. Shreyas Kalantri discusses PROTEUS's practice-changing takeaways for high-risk prostate cancer and the open questions future studies still need to answer.

Dr. Shreyas Kalantri reviews the safety profile of apalutamide plus ADT in PROTEUS, including rash management and comparable grade 3/4 adverse event rates.

Dr. Shreyas Kalantri explains how PSMA PET imaging revealed the metastasis-free survival benefit in PROTEUS that conventional imaging alone missed.

Dr. Shreyas Kalantri outlines the phase 3 PROTEUS trial design, showing perioperative apalutamide plus ADT improved pathologic response and metastasis-free survival.

The platinum-free interval is prognostic but not predictive for lenvatinib plus pembrolizumab, Susana Campos, MD, MPH, told CancerNetwork.

Experts compared outcomes for NALIRIFOX in patients with metastatic pancreatic cancer based on real-world and clinical trial data.

Five-year follow-up showed 37% overall survival rate with lenvatinib plus pembrolizumab in dMMR endometrial cancer.

Up to 55% of endometrial tumors show HER2/neu heterogeneity, explained Susana Campos, MD, MPH, making biopsy at recurrence key for ADC eligibility.

Andrew Evens, DO & Joanna Rhodes, MD, on CLL's transformation, CAR-T vs bispecifics, Hodgkin survivorship, and delivering world-class lymphoma care across NJ.

Experts discussed proactive strategies for managing diarrhea and making dose reduction decisions with NALIRIFOX in pancreatic cancer.

In the third debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a Child-Pugh A, BCLC stage B patient eligible for locoregional therapy, asking whether clinicians should prioritize locoregional treatment or introduce systemic therapy earlier.

In the second debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a treatment-naive patient with Child-Pugh B7, BCLC stage C disease and compromised liver function, asking how limited liver reserve should influence frontline selection.

A retrospective series found a 75% response rate adding lenvatinib after pembrolizumab progression in dMMR endometrial cancer, said Susana Campos, MD, MPH.

Experts discussed how NALIRIFOX compares with FOLFIRINOX and gemcitabine/nab-paclitaxel as frontline therapy for metastatic pancreatic cancer.

Barbara Burtness, MD, outlined the rationale behind OrigAMI-4 eligibility criteria and how tumor boards can select patients with HNSCC for amivantamab.

Following the MAJESTEC-3 presentation, the faculty discuss how the trial findings may influence the evolving treatment landscape for relapsed/refractory multiple myeloma (R/R MM).

Treatment until progression may not be the way forward with bispecific antibodies, according to Hans Lee, MD.

Dr. Harsh Parmar presents results from the phase 3 MAJESTEC-3 trial evaluating the combination of teclistamab and daratumumab versus standard daratumumab-based regimens in patients with relapsed/refractory multiple myeloma (R/R MM) who had received one to three prior lines of therapy.

Barbara Burtness, MD, discussed strategies for managing skin reactions and MET-driven edema in head and neck cancer treated with subcutaneous amivantamab.

Laura Alder, MD, discussed how her team at Duke monitors and educates patients for immune-related toxicities while receiving tarlatamab for brain metastases.

Hans Lee, MD, said it is only a matter of time before bispecific antibodies move into the newly diagnosed multiple myeloma setting.

In this segment, Isabel Curtin, LCSW, discusses the emotional and practical challenges that patients and families may face while navigating relapsed/refractory multiple myeloma and multiple lines of therapy.

In this opening segment, Samantha Shenoy, NP, introduces the From All Angles discussion and is joined by Elizabeth Bohannon, who shares her experience living with multiple myeloma, and Isabel Curtin, LCSW, who provides a psychosocial and supportive care perspective.

Experts emphasize that ongoing communication, whether from an academic or community oncology standpoint, is key for providing optimal multiple myeloma care.

Laura Alder, MD, discussed how tarlatamab’s intracranial activity compared with chemotherapy and radiation options for brain metastases in small cell lung cancer.

The discussion turns to the TOPAZ-1 study design and its long-term efficacy update.

Cell therapy will eventually become a part of the therapeutic strategy for newly diagnosed multiple myeloma, according to Joshua Richter, MD.

Laura Alder, MD, outlined the 3 objectives behind a retrospective analysis evaluating tarlatamab’s efficacy and safety in patients with SCLC and brain metastases.

Experts outline how certain practices may have an “incomplete understanding” of where the multiple myeloma field is today.

The phase 1b PRISM study is assessing the ability of ruxolitinib/retifanlimab to reinvigorate the tumor microenvironment in immune-resistant RCC.